GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis

OBJECTIVES: To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. METHODS: Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatol...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieira-Sousa, Elsa, Alves, Pedro, Rodrigues, Ana M, Teixeira, Filipa, Tavares-Costa, Jose, Bernardo, Alexandra, Pimenta, Sofia, Pimentel-Santos, Fernando M, Gomes, João Lagoas, Aguiar, Renata, Pinto, Patrícia, Videira, Taciana, Catita, Cristina, Santos, Helena, Borges, Joana, Sequeira, Graça, Ribeiro, Célia, Teixeira, Lídia, Ávila- Ribeiro, Pedro, Martins, Fernando M, Canhão, Helena, McInnes, Iain B., Ribeiro, Ruy M, Fonseca, João Eurico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147178/
https://www.ncbi.nlm.nih.gov/pubmed/32193187
http://dx.doi.org/10.1136/annrheumdis-2019-216500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147178/
https://www.ncbi.nlm.nih.gov/pubmed/32193187
http://dx.doi.org/10.1136/annrheumdis-2019-216500

Ejemplares similares